Movevit (Mesalazine)

Mesalazine acts locally in the colon to inhibit cyclooxygenase and lipoxygenase enzymes, scavenge free radicals, and modulate cytokine production. These actions collectively reduce inflammation of the intestinal mucosa without requiring high systemic drug levels.

The dosage of Movevit is individualized by the prescribing clinician based on disease severity, location, and patient response. Healthcare professionals determine the appropriate strength, frequency, and duration of therapy for each patient.

The pregnancy safety category for mesalazine is not definitively established. Clinicians should evaluate the potential benefits against possible risks before prescribing Movevit to pregnant or nursing women, and discuss any concerns with the patient.

To place an order, submit an enquiry on the Movevit product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Movevit delivers mesalazine via a rectal route, offering direct colonic exposure which can be advantageous for distal disease. Compared with oral 5‑ASA formulations, rectal delivery may achieve higher local concentrations with fewer systemic side effects, but suitability depends on disease location and patient preference.

Store Movevit at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Movevit is a rectal suppository. The patient should insert the suppository gently into the rectum, preferably after a bowel movement and before lying down, following the instructions provided by the healthcare professional.

Serious risks include severe allergic reactions, acute colitis, blood dyscrasias such as leukopenia or thrombocytopenia, pancreatitis, hepatotoxicity, and renal impairment. Patients should be monitored regularly for signs of these conditions, and therapy should be stopped if they occur.

Movevit should be avoided in patients with known hypersensitivity to mesalazine or any component of the formulation, in those with severe hepatic impairment, and in individuals who have experienced serious adverse reactions to other 5‑ASA products.